TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16699438

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses (Bausch & Lomb SofLens Multifocal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Monovision contact lenses (SofLens 59)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Monovision contact lenses
Number of subjects: 38
Study: 14740177

Group type: COMPARATOR
Intervention: Normal MPI (SSS=0, n=153)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Reversible defects (SDS≥3, n=65)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Irreversible defects (SDS<3 and SRS>1, n=100)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Irreversible defects with symptoms
Number of subjects: 318

Group type: COMPARATOR
Intervention: Normal MPI (SSS=0)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Reversible defects (SDS≥3)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Irreversible defects (SDS<3 and SRS>1)
Number of subjects: 318
Study: 12447951

Group type: COMPARATOR
Intervention: Doxorubicin (Group A, n = 39)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epirubicin (Group B, n = 40)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Patients 20 years of age or less
Number of subjects: 79

Group type: COMPARATOR
Intervention: Patients older than 20 years
Number of subjects: 79
Study: 9722818

Group type: EXPERIMENTAL
Intervention: Needle exchange program (NEP)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Standard referrals
Number of subjects: 325
Study: 8564938

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention including health education, stress management, and coping skills teaching
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study: 2507875

Group type: EXPERIMENTAL
Intervention: GRF group (n = 6) - repetitive GRF 1 micrograms/kg, IV, three times a week
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo group (n = 6) - saline injections
Number of subjects: 8
Study: 16806

Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid Maalox, 30 ml, 1 and 3 hr after a meal
Number of subjects: 0
Study: 31616932

Group type: EXPERIMENTAL
Intervention: Avocado diet (1 Hass avocado, ∼136 g per day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Moderate-fat diet (high oleic acid oils)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lower-fat diet
Number of subjects: 45
Study: 30670518

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation for CRRT
Number of subjects: 1450

Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation for CRRT
Number of subjects: 1450
Study: 27314311

Group type: EXPERIMENTAL
Intervention: Health-focused mortality salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social-focused mortality salience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 25611313

Group type: EXPERIMENTAL
Intervention: Belinostat plus paclitaxel/carboplatin (group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin alone (group B)
Number of subjects: 89
Study: 24488582

Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN) 15 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: micronized progesterone (MP) 200 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: micronized progesterone (MP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: lynestrenol (LYN) and micronized progesterone (MP)
Number of subjects: 60
Study: 23082173

Group type: EXPERIMENTAL
Intervention: Intermittent IL-2
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 267
Study: 20804358

Group type: EXPERIMENTAL
Intervention: Abrupt cessation (full-time occlusion discontinued completely at the start of the study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Therapy tapering (occlusion reduced from full-time to 50% of waking hours, then to 25%, and discontinued at week 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (abrupt cessation and therapy tapering)
Number of subjects: 20
Study: 18091051

Group type: EXPERIMENTAL
Intervention: WBRT + efaproxiral
Number of subjects: 106

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 106
Study: 15304276

Group type: EXPERIMENTAL
Intervention: Fluoride cement
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Porous coated press‐fit cup with ceramic coating
Number of subjects: 90

Group type: COMPARATOR
Intervention: Palacos cum Gentamicin cement
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cemented cups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Uncemented cups
Number of subjects: 90
Study: 11488185

Group type: EXPERIMENTAL
Intervention: Screening for breast cancer with mammography (WE study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative statistical analysis of WE study
Number of subjects: 0
Study: 9612666

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0
Study: 7853130

Group type: EXPERIMENTAL
Intervention: M + SRP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: M
Number of subjects: 51

Group type: COMPARATOR
Intervention: NoTx
Number of subjects: 51
Study: 29532635

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts incorporated in gels (protein, fiber, lipid)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gels rich in precursors (glucoraphanin and glucoiberin)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control broccoli sprout
Number of subjects: 5
Study: 27689900

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management (CBSM)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Psychoeducation control group
Number of subjects: 51
Study: 24901128

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) and laparoscopic common bile duct exploration (LCBDE) plus T‐tube drainage (group LT)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) and laparoscopic common bile duct exploration (LCBDE) with endonasobiliary drainage (ENBD) tube (group LE)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy with ENBD followed by LC (group EE)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: T‐tube drainage of open CBDE (group OT)
Number of subjects: 178
Study: 21940695

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections to parotid and submandibular glands (5 individuals)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections to submandibular glands only (1 individual)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adverse effects reported
Number of subjects: 6
Study: 20227758

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg subcutaneously every week for 26 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 51
Study: 18349870

Group type: EXPERIMENTAL
Intervention: Smoked cannabis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further trials of cannabis
Number of subjects: 0
Study: 17015055

Group type: EXPERIMENTAL
Intervention: Thioguanine
Number of subjects: 1492

Group type: COMPARATOR
Intervention: Mercaptopurine
Number of subjects: 1492
Study: 14523294

Group type: EXPERIMENTAL
Intervention: 1-week-on, 1-week-off therapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Triple nucleotide therapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Didanosine, Stavudine, Saquinavir, Ritonavir
Number of subjects: 600
Study: 10797160

Group type: EXPERIMENTAL
Intervention: Home intervention group (n=58)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care group (n=56)
Number of subjects: 114
Study: 8973677

Group type: EXPERIMENTAL
Intervention: RigiScan portable home monitor
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RigiScan Plus quantitative program
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clinical estimate of penetrable rigidity
Number of subjects: 10
Study: 1458665

Group type: EXPERIMENTAL
Intervention: 5% amorolfine nail lacquer, once-weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% amorolfine nail lacquer, twice-weekly
Number of subjects: 0
Study: 3974889

Group type: EXPERIMENTAL
Intervention: True plasmapheresis (PP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham plasmapheresis (sham PP)
Number of subjects: 54
Study: 29565472

Group type: EXPERIMENTAL
Intervention: Novel device (LINGUAL RING Ri.P.A.Ra) applied for a maximum of three months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (CG) with no treatment
Number of subjects: 80
Study: 27116921

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 25566783

Group type: EXPERIMENTAL
Intervention: Proactive primary care approach with in-home assessment and interdisciplinary care
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Proactive primary care approach
Number of subjects: 346
Study: 23419356

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided suprascapular nerve block (UG SNB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electrophysiology-guided suprascapular nerve block (EG SNB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Blind suprascapular nerve block (control group)
Number of subjects: 52
Study: 20130492

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: No breast-feeding
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Common exposure to both OCs and HT
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: ROC curve of the logistic function
Number of subjects: 493
Study: 19512937

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV) + zidovudine/lamivudine
Number of subjects: 106

Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) + zidovudine/lamivudine
Number of subjects: 106
Study: 15681688

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 47

Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 47
Study: 12856210

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DAA)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 10230741

Group type: EXPERIMENTAL
Intervention: Fluid extract of Echinacea purpurea (4 mL twice a day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (4 mL juice twice a day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fluid extract of Echinacea purpurea
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 8906176

Group type: EXPERIMENTAL
Intervention: Normothermic ischemia with warm blood cardioplegia
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Longer LTOC
Number of subjects: 720
Study: 1867225

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral sustained-release verapamil (verapamil-SR)
Number of subjects: 58
Study: 6344906

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard treatment combined with compression bandages
Number of subjects: 93
Study: 26398184

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 0
Study: 27223668

Group type: EXPERIMENTAL
Intervention: Levosulpiride (25-50 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Haloperidol (10-20 mg/d)
Number of subjects: 60
Study: 24126070

Group type: EXPERIMENTAL
Intervention: Slow-onset ACS presentation
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Fast-onset ACS presentation
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of delay factors
Number of subjects: 893
Study: 22816227

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 19925256

Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid (GDAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaviscon Liquid (GL)
Number of subjects: 0
Study: 18054420

Group type: EXPERIMENTAL
Intervention: silymarin (0.8 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: silymarin+yacon (0.8+2.4 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: silymarin+maca (0.6+0.2 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: maca (0.6 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: silymarin+yacon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: maca (high doses)
Number of subjects: 0
Study: 16386979

Group type: EXPERIMENTAL
Intervention: PC IOL
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: AC IOL
Number of subjects: 143

Group type: COMPARATOR
Intervention: ICS group
Number of subjects: 143
Study: 12755242

Group type: EXPERIMENTAL
Intervention: 1.5 mg prostaglandin E2 vaginal tablets
Number of subjects: 241

Group type: COMPARATOR
Intervention: 3 mg prostaglandin E2 vaginal tablets
Number of subjects: 241
Study: 10996361

Group type: EXPERIMENTAL
Intervention: Patients with triple vessel disease (TVD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Patients with normal coronary angiogram (NCA)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation of CD105 with active TGFbeta1 and (a+l)TGFbeta1
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Correlation of CD105 with TGFbeta3 and CD105/TGFbeta3 complexes
Number of subjects: 97
Study: 9229826

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate aerosol treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8317408

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 3315425

Group type: EXPERIMENTAL
Intervention: Computer feedback of weighting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outcome feedback alone (Control)
Number of subjects: 0
Study: 29133365

Group type: EXPERIMENTAL
Intervention: Current smoking (at the time of diagnosis)
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Smoked 20 or more years
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Smoked within 5 years of diagnosis
Number of subjects: 1888
Study: 26363332

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 76
Study: 25346026

Group type: EXPERIMENTAL
Intervention: Acupressure at specific acupoints (Fengchi (GB20), Baihui (GV20), Shenmen (HT7), Niguan (PC6), Yingtang (EX-HN3))
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham-acupressure (pressure on five non-acupoints)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care (no intervention apart from nursing home care)
Number of subjects: 99
Study: 23122405

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of PPTA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of PPTA
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of PPTA
Number of subjects: 31
Study: 20187249

Group type: EXPERIMENTAL
Intervention: Gene therapy approaches to increase levels of endogenous dopamine or enhance the function of levodopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy approaches to normalize basal ganglia circuitry by reducing PD-related overactivity of specific brain structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene delivery of trophic factors to augment dopaminergic function
Number of subjects: 0
Study: 17850566

Group type: EXPERIMENTAL
Intervention: Cuff pressure measurement during insertion of a gastric tube
Number of subjects: 30

Group type: COMPARATOR
Intervention: Measurement of exhaled CO2 through the gastric tube
Number of subjects: 30
Study: 16076684

Group type: EXPERIMENTAL
Intervention: H. pylori-positive subjects
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: PCA-positive H. pylori-positive subjects
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: PCA-positive H. pylori-negative subjects
Number of subjects: 912

Group type: COMPARATOR
Intervention: PCA-negative H. pylori-negative subjects
Number of subjects: 912
Study: 11743305

Group type: EXPERIMENTAL
Intervention: Interrupted current delivery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous current delivery
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 12
Study: 19667500

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 to 225 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9457980

Group type: EXPERIMENTAL
Intervention: Maternal serum creatine kinase levels in tubal pregnancies
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in normal pregnancies (control group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in missed abortions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in pelvic inflammatory disease
Number of subjects: 90

Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in acute appendicitis
Number of subjects: 90
Study: 1771401

Group type: EXPERIMENTAL
Intervention: Rheumajecta and Vasolastine (R & V)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 34
Study: 7137200

Group type: EXPERIMENTAL
Intervention: Active alcoholics
Number of subjects: 625

Group type: COMPARATOR
Intervention: Nonalcoholics
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Patients initially classified as alcoholic
Number of subjects: 625
Study: 30686103

Group type: EXPERIMENTAL
Intervention: Lower BP target arm (<130 mm Hg)
Number of subjects: 2454

Group type: COMPARATOR
Intervention: Higher BP target arm (130 to 149 mm Hg)
Number of subjects: 2454
Study: 29254910

Group type: EXPERIMENTAL
Intervention: Intervention messages delivered via the Tú decides app
Number of subjects: 1310

Group type: COMPARATOR
Intervention: Control messages about trial participation
Number of subjects: 1310
Study: 26881208

Group type: EXPERIMENTAL
Intervention: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T) for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T)
Number of subjects: 0
Study: 23595613

Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg three times daily for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 22095057

Group type: EXPERIMENTAL
Intervention: Back School program (BSG, N.=29)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical assistance (CG, N.=21)
Number of subjects: 50
Study: 20595542

Group type: EXPERIMENTAL
Intervention: Alternating current EMS (2.5 kHz delivered at 75 Hz, 400 micros)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pulsed current EMS (75 Hz, 400 micros)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alternating current EMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pulsed current EMS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both EMS conditions
Number of subjects: 12
Study: 18047925

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day) for 3 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Candesartan and Valsartan (both groups)
Number of subjects: 95
Study: 15650042

Group type: EXPERIMENTAL
Intervention: Psychosocial counselling intervention (three sessions with a social worker trained in Experiential Psychosocial Therapy: one before, one during, and one after the first IVF cycle)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine-care control group
Number of subjects: 84
Study: 12395333

Group type: EXPERIMENTAL
Intervention: Tamoxifen 120 mg/d (TMX120)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Tamoxifen 60 mg/d (TMX60)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 329
Study: 10092165

Group type: EXPERIMENTAL
Intervention: Muscle relaxation training (30 minutes, twice a week for 10 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 7594701

Group type: EXPERIMENTAL
Intervention: cp-45 vaccine (10^4 or 10^5 TCID50)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: cp-45 vaccine (10^5 TCID50)
Number of subjects: 114
Study: 2316411

Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Peer-led intervention with booster sessions
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Teacher-led intervention
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Teacher-led intervention with booster sessions
Number of subjects: 998

Group type: COMPARATOR
Intervention: Control
Number of subjects: 998
Study: 6576204

Group type: EXPERIMENTAL
Intervention: Radiation doses of less than or equal to 18 Gy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Radiation doses of 24 Gy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Intensive systemic reinduction therapy
Number of subjects: 275
Study: 30859618

Group type: EXPERIMENTAL
Intervention: Monovalent PHF vaccine administered at separate sites
Number of subjects: 91

Group type: COMPARATOR
Intervention: Multivalent PHF/Rabies vaccine administered at a single site
Number of subjects: 91